Market ExpansionBriumvi is now commercially available in additional countries in the EU, UK, and Switzerland, which could translate into incrementally larger royalty revenue in the quarters ahead.
Revenue GrowthTG Therapeutics reported $120MM of US net Briumvi revenue, representing +11% Q/Q growth driven by a combination of new and repeat prescriptions.
Stock RatingAnalyst maintains a Buy rating for TG Therapeutics stock, indicating confidence in its potential.